News

Result of Annual General Meeting (AGM)
Result of Annual General Meeting (AGM)
May 5, 2021

Result of Annual General Meeting (AGM)

Annual General Meeting (AGM) Statement
Annual General Meeting (AGM) Statement
May 5, 2021

Annual General Meeting (AGM) Statement

Director/PDMR Shareholding
Director/PDMR Shareholding
April 19, 2021

The Company has received notification from Roger McDowell, a Director of the Company, that on 16 April 2021 he purchased 900,000 Ordinary Shares in the Company at a price of 5.00p per share.

Director/PDMR Shareholding
Director/PDMR Shareholding
April 14, 2021

The Company has received notification from Richard Dennis, Chief Commercial Officer, that on 12 April and 13 April 2021 he purchased, in aggregate, 625,000 Ordinary Shares in the Company at an average price of 5.22p per share. Richard Dennis now holds 625,000 Ordinary Shares in the Company, which represents approximately 0.21% of the issued share capital of the Company.

Annual Report and Financial Statements 31 December 2020
Annual Report and Financial Statements 31 December 2020
April 6, 2021

The Annual Report and Financial Statements for the year ended 31 December 2020, together with a notice of the Annual General Meeting is available to view on the Companies website www.proteomics.com and will be posted to shareholders imminently.

Holding(s) in Company
Holding(s) in Company
April 1, 2021

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 31 March 2021.

Investor Presentation
Investor Presentation
April 1, 2021

Proteome Sciences PLC is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company’s results for the year ended 31 December 2020 via the Investor Meet Company platform on Thursday, 8 April 2021 at 10.00am BST.

Final results for the year ended 31 December 2020
Final results for the year ended 31 December 2020
April 1, 2021

The Company is pleased to announce its audited results for the year ended 31 December 2020.

Loan amendment
Loan amendment
March 30, 2021

On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited (“VIM”) (the “Loan”).  The Directors of Proteome Sciences are now pleased to announce that the Loan has been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest is now repayable on 1 May 2022 (previously 1 May 2021) (the “Loan Amendment”).  All other terms of the Loan remain the same as announced on 3 July 2018, including that interest will accrue at the annual rate of 2.5 per cent. above the UK sterling base rate of Barclays Bank plc.

Holdings in Company
Holdings in Company
March 29, 2021

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 29 March 2021.